UK markets closed

Vericel Corporation (VCEL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
32.83+0.02 (+0.06%)
At close: 04:00PM EST
32.83 0.00 (0.00%)
After hours: 04:31PM EST

Vericel Corporation

64 Sidney Street
Cambridge, MA 02139
United States
617 588 5555

Full-time employees273

Key executives

NameTitlePayExercisedYear born
Mr. Dominick C. Colangelo Esq.CEO, Pres & Director1.19M548.75k1964
Mr. Michael HalpinChief Operating Officer585.43k896.26k1961
Mr. Sean C. FlynnVP, Gen. Counsel & Sec.502.69kN/A1974
Dr. Jonathan M. HopperChief Medical Officer523.68k720.35k1962
Mr. Joseph Anthony Mara Jr.CFO, Principal Accounting Officer & TreasurerN/AN/A1976
Mr. Eric BurnsExec. Director of Financial Planning and Analysis & Investor RelationsN/AN/AN/A
Mr. Patrick J. FowlerSr. VP of Corp. Devel. & StrategyN/AN/AN/A
Ms. Heidi HassenVP of HRN/AN/AN/A
Mr. Roland DeAngelisSr. VP of Commercial OperationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Vericel Corporation’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 4; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.